Log In
Print
BCIQ
Print
Print this Print this
 

PrandiMet (repaglinide/metformin)

Also known as: MetPrandin

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionCombination of repaglinide, a short-acting beta-cell stimulating meglitinide and metformin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Shionogi & Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today